Cardiff Oncology, Inc. Common Stock (CRDF) Stock Price

CRDFStock

$0.90−59.77%52W

Market Cap$70.10M

P/E—

PEG Ratio—

Div yield—

Beta1.51

CRDF Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-54.62%

Price vs S&P 500 (4W)-32.90%

VGM Score35.74

Book Value / Share (Quarterly)$0.39

P/TBV (Annual)0.50x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)14.99%

Cash Flow / Share (Quarterly)$-0.60

Price vs S&P 500 (YTD)-79.86%

Gross Margin (TTM)100.00%

Net Profit Margin (TTM)-7884.06%

EPS (TTM)$-0.59

10-Day Avg Trading Volume0.44M

EPS Excl Extra (TTM)$-0.59

Revenue Growth (5Y)9.89%

EPS (Annual)$-0.69

ROI (Annual)-101.02%

Gross Margin (Annual)100.00%

Net Profit Margin (5Y Avg)-8131.43%

Cash / Share (Quarterly)$0.50

Revenue Growth QoQ (YoY)-14.05%

ROA (Last FY)-74.09%

Revenue Growth TTM (YoY)-6.96%

EBITD / Share (TTM)$-0.62

ROE (5Y Avg)-54.35%

Operating Margin (TTM)-8320.08%

Cash Flow / Share (Annual)$-0.56

P/B Ratio2.64x

P/B Ratio (Quarterly)3.35x

Net Income / Employee (Annual)$-1,479,100

EV / Revenue (TTM)119.89x

Net Interest Coverage (TTM)-100.63x

ROA (TTM)-75.51%

EPS Incl Extra (Annual)$-0.69

Current Ratio (Annual)3.67x

Quick Ratio (Quarterly)3.21x

3-Month Avg Trading Volume1.07M

52-Week Price Return-59.77%

Revenue / Employee (TTM)$16,400

Tangible BV / Share (Quarterly)$1.74

P/S Ratio (Annual)118.21x

Asset Turnover (Annual)0.01x

52-Week High$3.31

Operating Margin (5Y Avg)-8586.53%

EPS Excl Extra (Annual)$-0.69

CapEx CAGR (5Y)-26.84%

Tangible BV CAGR (5Y)74.85%

26-Week Price Return-44.72%

Quick Ratio (Annual)3.59x

13-Week Price Return2.40%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)3.30x

Enterprise Value$60.90M

Revenue / Share Growth (5Y)-12.85%

Asset Turnover (TTM)0.01x

Book Value / Share Growth (5Y)-28.19%

Revenue / Employee (Annual)$19,100

Pretax Margin (Annual)-7732.04%

Cash / Share (Annual)$0.85

3-Month Return Std Dev67.53%

Gross Margin (5Y Avg)-134.65%

Net Income / Employee (TTM)$-1,292,000

ROE (Last FY)-101.02%

Net Interest Coverage (Annual)-65.17x

EPS Basic Excl Extra (Annual)$-0.69

Receivables Turnover (TTM)1.42x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-0.59

Receivables Turnover (Annual)0.72x

ROI (TTM)-103.08%

P/S Ratio (TTM)137.99x

Pretax Margin (5Y Avg)-8131.43%

Revenue / Share (Annual)$0.01

Tangible BV / Share (Annual)$2.38

Price vs S&P 500 (52W)-75.30%

Year-to-Date Return-67.93%

5-Day Price Return-13.36%

EPS Normalized (Annual)$-0.69

ROA (5Y Avg)-44.76%

Net Profit Margin (Annual)-7732.04%

Month-to-Date Return-25.53%

Cash Flow / Share (TTM)$-0.91

EBITD / Share (Annual)$-0.73

Operating Margin (Annual)-8256.32%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-54.35%

LT Debt / Equity (Quarterly)0.01x

EPS Basic Excl Extra (TTM)$-0.59

P/TBV (Quarterly)0.68x

P/B Ratio (Annual)4.17x

Pretax Margin (TTM)-7884.06%

Book Value / Share (Annual)$0.66

Price vs S&P 500 (13W)-0.29%

Beta1.51x

Revenue / Share (TTM)$0.01

ROE (TTM)-103.08%

52-Week Low$0.76

vGradeD

gGradeC

mGradeC

vgmGradeD

CRDF Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 11, 2026	-$0.16	-$0.14	+12.50%(+$0.02)
Q1 2026	May 14, 2026	-$0.12	-$0.18	-45.16%(-$0.06)
Q4 2025	Feb 24, 2026	-$0.20	-$0.11	+44.07%(+$0.09)
Q3 2025	Nov 6, 2025	-$0.21	-$0.17	+18.40%(+$0.04)
Q2 2025	Jul 29, 2025	-$0.20	-$0.21	-6.78%(-$0.01)

CRDF Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.07

3.86

3.75

Industry Peers — Biological Products(186)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
CRDFCardiff Oncology, Inc. Common Stock	D	C	C	138.0x	-7.0%	100.0%	—	$0.90
AMGNAmgen Inc	D	C	A	6.1x	9.1%	74.3%	2.9%	$432.49
GILDGilead Sciences Inc	C	B	A	6.4x	5.5%	79.6%	133.6%	$156.19
MRNAModerna, Inc. Common Stock	F	C	A	39.1x	-27.6%	36.4%	—	$218.01
ARGXargenx SE American Depositary Shares	D	A	B	6.6x	165.2%	89.8%	—	$819.14
RVMDRevolution Medicines, Inc. Common Stock	F	—	B	3296.2x	—	—	—	$177.96
BIIBBiogen Inc. Common Stock	C	D	A	3.4x	0.3%	74.0%	-18.8%	$232.65
BNTXBioNTech SE American Depositary Share	C	C	C	7.6x	-11.8%	79.2%	—	$87.71
EXELExelixis Inc	C	B	A	6.3x	9.2%	96.5%	31.1%	$62.23
HALOHalozyme Therapeutics, Inc.	D	B	A	8.3x	41.1%	82.4%	22.9%	$121.84
NBIXNeurocrine Biosciences Inc	C	B	B	4.1x	34.4%	98.0%	2.3%	$135.71
TECHBio-Techne Corp.	D	C	B	9.4x	-0.4%	66.2%	6.0%	$72.57
RGENRepligen Corp	F	C	A	14.2x	16.5%	53.8%	-4.9%	$175.42
APGEApogee Therapeutics, Inc. Common Stock	—	—	A	—	—	—	—	$135.07
PCVXVaxcyte, Inc. Common Stock	—	—	B	—	—	—	—	$63.62
IBRXImmunityBio, Inc. Common Stock	F	A	A	58.7x	192.9%	99.3%	—	$9.18
QGENQIAGEN N.V.	C	C	B	4.5x	3.0%	62.5%	4.2%	$46.13
KRYSKrystal Biotech, Inc. Common Stock	D	B	B	21.3x	22.6%	94.6%	—	$316.58
TWSTTwist Bioscience Corporation Common Stock	D	B	A	20.2x	19.2%	52.0%	—	$132.75
KYMRKymera Therapeutics, Inc. Common Stock	F	B	B	83.0x	134.8%	—	—	$104.78
IOVAIovance Biotherapeutics, Inc. Common Stock	D	B	A	19.0x	34.5%	48.4%	—	$13.62
IMVTImmunovant, Inc. Common Stock	—	—	C	—	—	—	—	$26.73
KODKodiak Sciences Inc Common Stock	—	—	A	—	—	—	—	$85.75
CGONCG Oncology, Inc. Common stock	F	A	B	851.8x	1030.3%	-85.2%	—	$59.85
SRRKScholar Rock Holding Corporation Common Stock	F	—	C	102.7x	—	—	—	$39.90
CRSPCRISPR Therapeutics AG	D	B	B	355.6x	-64.8%	—	—	$49.25
ADPTAdaptive Biotechnologies Corporation Common Stock	D	B	B	12.4x	50.1%	75.6%	—	$24.02
RLAYRelay Therapeutics, Inc. Common Stock	F	D	B	344.7x	23.9%	—	—	$16.28
TARSTarsus Pharmaceuticals, Inc. Common Stock	D	A	B	5.5x	105.2%	93.3%	—	$68.07
DNLIDenali Therapeutics Inc. Common Stock	F	—	C	781.1x	—	—	—	$17.61
BEAMBeam Therapeutics Inc. Common Stock	D	B	C	15.5x	158.9%	—	—	$23.47
ADMAADMA Biologics, Inc.	C	C	B	4.7x	8.0%	64.7%	—	$10.68
VCELVericel Corporation	D	B	B	6.7x	22.9%	74.6%	38.9%	$40.13
BCRXBioCryst Pharmaceuticals Inc	B	A	B	2.1x	68.7%	97.8%	—	$7.79
RXRXRecursion Pharmaceuticals, Inc. Class A Common Stock	D	C	C	33.9x	-15.1%	3.5%	—	$3.46
NVAXNovavax Inc	C	D	B	4.5x	-61.6%	79.2%	—	$11.26
ALVOAlvotech Ordinary Shares	D	D	B	3.9x	-12.1%	60.7%	—	$5.00
MESOMesoblast Limited American Depositary Shares	D	A	C	14.6x	599.2%	86.1%	—	$13.28
VIRVir Biotechnology, Inc. Common Stock	B	B	B	5.6x	1496.1%	100.0%	—	$9.96
MAZEMaze Therapeutics, Inc. Common Stock	—	A	B	—	700.0%	—	—	$27.53
IMCRImmunocore Holdings plc American Depositary Shares	D	B	B	3.5x	20.9%	98.9%	—	$29.40
COAGHemab Therapeutics Holdings, Inc. Common Stock	—	—	C	—	—	—	—	$30.07
INBXInhibrx Biosciences, Inc. Common Stock	D	C	A	944.3x	550.0%	—	—	$89.83
TSHATaysha Gene Therapies, Inc. Common Stock	D	C	D	120.7x	-32.3%	—	—	$3.62
IMTXImmatics N.V. Ordinary Shares	C	C	C	21.5x	-68.0%	—	—	$6.73
REPLReplimune Group, Inc.	—	—	B	—	—	—	—	$10.86
VORVor Biopharma Inc. Common Stock	—	—	C	—	—	—	—	$18.03
MGTXMeiraGTx Holdings plc Ordinary Shares	C	A	C	2.2x	948.4%	98.0%	—	$9.28
SLBTSL Science Holding Limited Ordinary Shares	—	—	D	—	—	—	—	$1.53
CGEMCullinan Therapeutics, Inc. Common Stock	—	—	C	—	—	—	—	$12.93
GLUEMonte Rosa Therapeutics, Inc. Common Stock	D	F	D	28.9x	-83.9%	—	—	$9.74

About Cardiff Oncology, Inc. Common Stock

Cardiff Oncology is a clinical-stage biotechnology company developing onvansertib, an oral PLK1 inhibitor designed to enhance standard cancer treatments through combination therapy. The company is advancing clinical trials in RAS-mutated metastatic colorectal cancer, pancreatic cancer, small cell lung cancer, triple negative breast cancer, and chronic myelomonocytic leukemia.